Oncotype DX Breast Recurrence Score®

How to interpret the Oncotype DX® test results?

For your patients with HR+, HER2-, early-stage, invasive breast cancer

The Oncotype DX Breast Recurrence Score report provides three points of clarity to aid in treatment decisions (chemotherapy, yes or no) for node-negative and node-positive, hormone receptor-positive, HER2-negative, early-stage breast cancer patients.

3 pieces of information provided by the test

1

Recurrence Score result

This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score® result is used to predict the risk of the breast cancer returning at a distant site and whether chemotherapy may help reduce the risk.1,3-6

2

Distant recurrence risk at 9 yearsa

This percentage indicates the risk that the breast cancer will come back somewhere else in the body, “distant recurrence,” within 9 years when treated with hormonal therapy alone for 5 years.1,4,5

3

Absolute chemotherapy benefita

This percentage indicates the benefit expected from adding chemotherapy to hormonal therapy in order to reduce the risk of cancer recurrence or death for the recurrence score group.3,4,6

a These results are valid in HR+, HER2-, early-stage, invasive breast cancer patients treated with 5 years of endocrine therapy.

Explore the patient reports

Further Understanding the Results: Node-Negative Patients

Recurrence Score Result

Patients with a Recurrence Score result of 0-25 generally do not benefit from the addition of chemotherapy to endocrine therapy.2–4

Patients with Recurrence Score results 26–100 significantly benefit from the addition of chemotherapy to endocrine therapy.2,3

Further Understanding the Results: Node-Positive Patients

Recurrence Score Result

Patients with a Recurrence Score result of 0–17 do not benefit from the addition of chemotherapy to endocrine therapy.6–9

Patients with a Recurrence Score result of 18–30 can derive a potential benefit from the addition of chemotherapy to endocrine therapy.6,9

Patients with Recurrence Score results 31-100 significantly benefit from the addition of chemotherapy to endocrine therapy.6

Support Materials

Download clinician-to-patient discussion guides


START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
START REPORT GUIDE
ABBREVIATIONS
CT=chemotherapy
ER=oestrogen receptor
ET=endocrine therapy
HER2=human epidermal growth factor receptor 2
N1=node-positive
REFERENCES
  1. Paik et al. N Engl J Med. 2004.
  2. Paik et al. J Clin Oncol. 2006.
  3. Geyer et al. NPJ Breast Cancer. 2018.
  4. Sparano et al. N Engl J Med. 2018.
  5. Dowsett et al. J Clin Oncol. 2010.
  6. Albain et al. Lancet Oncol. 2010.
  7. Stemmer et al. NPJ Breast Cancer. 2017.
  8. Miller et al. ASCO. 2017.
  9. Nitz et al. Breast Cancer Res Treat. 2017.

Contact Us

Get in Touch
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.